Skip to content

    Sakar Healthcare

    SAKAR
    Healthcare·22 May 2026
    Management Summary

    Sakar Healthcare reported a strong Q4 and full-year FY26, driven by significant growth in its oncology division and improved operational efficiencies. Revenue, EBITDA, and PAT saw substantial year-on-year increases. The company is transitioning into a focused specialty oncology player with a robust pipeline of products and regulatory approvals, aiming for continued export-led growth and margin expansion in the coming years.

    Highlights

    5

    • Robust Q4 FY26 revenue growth of 42% YoY, reaching ₹71.097 crores.

    • Significant EBITDA expansion in Q4 FY26 by 67% YoY, with margins at 37%, driven by operational efficiencies and cost discipline.

    • Strong PAT growth of 91% YoY in Q4 FY26, reflecting improved profitability.

    • Oncology business is becoming a core growth engine, contributing 38% of FY26 revenues and expected to double next year.

    • Successful regulatory milestones with 12 marketing authorizations received and 5 tech transfer projects commercialized in Q1 FY27.

    Key financials

    Metrics

    7

    Periods

    2

    Q4 FY26

    4
    • Revenue
      ₹71.097 Cr
      YoY+41.5%
    • EBITDA
      ₹26.236 Cr
      YoY+66.8%
    • EBITDA Margin
      37%
    • PAT
      ₹11.024 Cr
      YoY+91.3%

    FY26

    3
    • Revenue
      ₹251.736 Cr
      YoY+41.8%
    • EBITDA
      ₹68.888 Cr
      YoY+38.7%
    • PAT
      ₹30.485 Cr
      YoY+74.2%

    Segment breakdown

    Oncology (FY26)
    38% Revenue Share
    Non-Oncology (FY26)
    62% Revenue Share
    Oncology (Q4 FY26)
    ₹31.46 Cr Revenue
    Non-Oncology (Q4 FY26)
    ₹39.64 Cr Revenue
    Oncology Export (Q4 FY26)
    ₹0.3 Cr Revenue
    Oncology Export (Q4 FY25)
    ₹0.22 Cr Revenue
    Total Export (Q4 FY26)
    ₹29 Cr Revenue
    Total Export (Q4 FY25)
    ₹26 Cr Revenue
    Domestic Oncology (Q4 FY26)
    ₹31 Cr Revenue
    List

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Revenue Growth
    0.40
    		Medium
    Revenue
    Accord Partnership Revenue
    INR50 crores to INR100 crores
    		Medium
    Revenue
    Oncology Revenue Growth
    doubling
    		Medium
    Revenue
    Bavla Oncology Facility Revenue
    INR800 crores to INR1,000 crores
    		Medium
    Revenue
    Oncology Revenue
    around INR500 crores
    		Medium
    Profitability
    Oncology EBITDA Margin
    25% to 30%
    		Medium
    Regulatory
    Dossier Approvals
    cross 300
    		Medium
    Business Development
    Overseas Business Contracts
    more than 100
    		Medium
    Capacity
    Oncology Plant Capacity Utilization
    50% to 55%
    		Medium
    Tax
    Tax Rate
    25%
    		High
    Revenue Mix
    Oncology Revenue Share
    0.60
    		Medium
    Revenue Mix
    Non-Oncology Revenue Share
    0.40
    		Medium
    Revenue Mix
    Oncology Export Share
    0.65
    		Medium
    Revenue Mix
    Oncology Domestic Share
    0.35
    		Medium
    Product Launch
    Commercialized Products
    25
    		Medium

    FY27 Revenue Growth

    next quarter
    Current42% in FY26
    Target40% growth in FY27

    Why it matters

    To verify if the company maintains its aggressive growth trajectory, especially with increasing oncology contribution.

    So just to summarize, you still expect 40% type of growth next year also. If everything goes well. Yes, that we are actually eyeing for the next financial year with the entire setup ready now for taking off.

    How to verify

    key_financials.metrics[label='Revenue (FY27)']

    Risks & concerns

    1
    RiskSeverity

    Impact of Middle East conflict on raw material/logistics

    Low dependency on Middle East for current business, and contracts allow passing on significant cost increases to partners. — Analyst downplayed

    medium

    Q&A highlights

    8

    “Yes, that we are actually eyeing for the next financial year with the entire setup ready now for taking off.”

    Analyst sought confirmation on the previously given INR380 crores revenue guidance for FY27, which management affirmed.

    asked by Rupesh Tatiya

    2 min read5 chapters

    Detailed Narrative

    01

    Oncology Business Transformation and Growth

    Sakar Healthcare is actively transforming into a focused specialty oncology company, with the oncology division contributing 38% of total revenues in FY26, a significant increase from 21% in FY25. This shift is supported by investments in oncology API, finished formulations, R&D capabilities, and a globally compliant manufacturing infrastructure. The company aims for oncology sales to almost double in the next year, targeting an initial milestone of around INR500 crores in oncology revenue within the next two years.

    02

    Strong Financial Performance in Q4 and FY26

    The company delivered robust financial results for Q4 FY26, with revenue from operations growing 42% YoY to ₹71.097 crores. EBITDA increased by 67% YoY to ₹26.2357 crores, achieving a 37% margin, while PAT surged 91% YoY to ₹11.0243 crores. For the full year FY26, revenue grew 42% to ₹251.736 crores, EBITDA increased 39% to ₹68.8882 crores, and PAT saw a 74% rise to ₹30.4846 crores, reflecting strong operational leverage and cost discipline.

    03

    Export-Led Growth Strategy and Pipeline

    Sakar Healthcare's growth is increasingly driven by exports, with Q4 FY26 export turnover at ₹29 crores, up from ₹26 crores in Q4 FY25. The company has signed over 60 oncology business contracts and has 35 ongoing discussions. It has filed 125 dossiers globally, with 12 marketing authorizations received. The Accord partnership alone represents a potential opportunity of INR50-100 crores in FY27, with 5 tech transfer projects already commercialized in Q1 FY27.

    04

    Capacity Utilization and Margin Outlook

    The Bavla oncology facility, designed for large-scale operations, currently operates at under 30% capacity utilization. Management expects this to increase to 50-55% within the next two years, supporting potential revenues of INR800-1,000 crores at optimal utilization without significant incremental capex. EBITDA margins in the oncology division are projected to remain in the range of 25-30% over the medium term⏳, with the Q4 FY26 margin of 37% attributed to operational efficiencies and cost reductions.

    05

    API Integration and Regulatory Milestones

    The company is focused on backward integration with its in-house developed APIs. It has received two CEPs (Gefitinib and Capecitabine) for its 21 cytotoxic APIs, enabling integrated API supplies for finished formulations in regulated markets. Two more API submissions are pending, and five additional APIs are planned. The goal is to cross 300 dossier approvals and achieve over 100 overseas business contracts within the next two years, with 25 products expected to be commercialized in FY27.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.